Clinical trials
Hypocalcemia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2013 | 5 |
| 2014 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 4 |
| National Institutes of Health Clinical Center (CC) | 3 |
| Calcilytix Therapeutics, Inc., a BridgeBio company | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| Shire | 2 |
| Sumitomo Pharma Switzerland GmbH | 2 |
| Abbott | 1 |
| Astra USA | 1 |
| Brooke Army Medical Center | 1 |
| Columbia University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypocalcemia | 29 |
| Hypoparathyroidism | 9 |
| Hyperparathyroidism, Secondary | 6 |
| Renal Insufficiency, Chronic | 4 |
| Hypercalciuria | 3 |
| Musculoskeletal Diseases | 3 |
| Calcium Metabolism Disorders | 2 |
| DiGeorge Syndrome | 2 |
| Immunologic Deficiency Syndromes | 2 |
| Metabolic Diseases | 2 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.